BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Pipili C, Cholongitas E. Μanagement of patients with hepatitis B and C before and after liver and kidney transplantation. World J Hepatol 2014; 6(5): 315-325 [PMID: 24868325 DOI: 10.4254/wjh.v6.i5.315] [Cited by in CrossRef: 9] [Cited by in F6Publishing: 9] [Article Influence: 1.1] [Reference Citation Analysis]
Number Citing Articles
1 Pipili C, Cholongitas E. Treatment of chronic hepatitis C in liver transplant candidates and recipients: Where do we stand? World J Hepatol 2015; 7(12): 1606-1616 [PMID: 26140081 DOI: 10.4254/wjh.v7.i12.1606] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 0.4] [Reference Citation Analysis]
2 Coppolino G, Simeoni M, Summaria C, Postorino MC, Rivoli L, Strazzulla A, Torti C, Fuiano G. The case of chronic hepatitis B treatment with tenofovir: an update for nephrologists. J Nephrol 2015;28:393-402. [DOI: 10.1007/s40620-015-0214-0] [Cited by in Crossref: 10] [Cited by in F6Publishing: 12] [Article Influence: 1.4] [Reference Citation Analysis]
3 Kornberg A. Intravenous immunoglobulins in liver transplant patients: Perspectives of clinical immune modulation. World J Hepatol 2015; 7(11): 1494-1508 [PMID: 26085909 DOI: 10.4254/wjh.v7.i11.1494] [Cited by in Crossref: 7] [Cited by in F6Publishing: 4] [Article Influence: 1.0] [Reference Citation Analysis]
4 Ridruejo E. Antiviral treatment for chronic hepatitis B in renal transplant patients. World J Hepatol 2015; 7(2): 189-203 [PMID: 25729474 DOI: 10.4254/wjh.v7.i2.189] [Cited by in Crossref: 12] [Cited by in F6Publishing: 12] [Article Influence: 1.7] [Reference Citation Analysis]
5 Battaglia Y, Cojocaru E, Forcellini S, Russo L, Russo D. Tenofovir and kidney transplantation: case report. Clin Nephrol Case Stud. 2016;4:18-23. [PMID: 29043137 DOI: 10.5414/cncs108929] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.2] [Reference Citation Analysis]
6 Pipili C, Cholongitas E. Pharmaceutical management of hepatitis B and C in liver and kidney transplant recipients. World J Gastrointest Pharmacol Ther 2015; 6(4): 105-110 [PMID: 26558143 DOI: 10.4292/wjgpt.v6.i4.105] [Cited by in CrossRef: 4] [Cited by in F6Publishing: 3] [Article Influence: 0.6] [Reference Citation Analysis]
7 Cholongitas E, Goulis I, Antoniadis N, Fouzas I, Imvrios G, Giakoustidis D, Giouleme O, Papanikolaou V, Akriviadis E, Vasiliadis T. Nucleos(t)ide analog(s) prophylaxis after hepatitis B immunoglobulin withdrawal against hepatitis B and D recurrence after liver transplantation. Transpl Infect Dis. 2016;18:667-673. [PMID: 27421122 DOI: 10.1111/tid.12575] [Cited by in Crossref: 19] [Cited by in F6Publishing: 15] [Article Influence: 3.2] [Reference Citation Analysis]
8 Cholongitas E, Tziomalos K, Pipili C. Management of patients with hepatitis B in special populations. World J Gastroenterol 2015; 21(6): 1738-1748 [PMID: 25684938 DOI: 10.3748/wjg.v21.i6.1738] [Cited by in CrossRef: 29] [Cited by in F6Publishing: 27] [Article Influence: 4.1] [Reference Citation Analysis]
9 Durante-Mangoni E, Vitrone M, Parrella A, Andini R, Iossa D, Ragone E, Falco E, Maiello C, Utili R, Zampino R. Efficacy and safety of tenofovir, entecavir, and telbivudine for chronic hepatitis B in heart transplant recipients. Transpl Infect Dis 2016;18:319-25. [PMID: 26988401 DOI: 10.1111/tid.12525] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 0.7] [Reference Citation Analysis]